Adicet Bio, Inc. Lease, Cost
Adicet Bio, Inc. (ACET) reported Lease, Cost of $854.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-05
- Adicet Bio, Inc. lease, cost for the quarter ending 2026-06-30 was $854.00K, a 16.11% decline year-over-year.
- Adicet Bio, Inc. lease, cost for the quarter ending 2026-03-31 was $823.00K, a 16.87% decline year-over-year.
- Adicet Bio, Inc. lease, cost for the quarter ending 2025-12-31 was $946.00K.
- Adicet Bio, Inc. lease, cost for the quarter ending 2025-09-30 was $840.00K, a 15.24% decline year-over-year.
- Adicet Bio, Inc. lease, cost for fiscal 2025 was $3.79M, a 3.97% decline from fiscal 2024.
- Adicet Bio, Inc. lease, cost for fiscal 2024 was $3.95M, a 1.00% decline from fiscal 2023.
- Adicet Bio, Inc. lease, cost for fiscal 2023 was $3.99M, a 1.37% increase from fiscal 2022.
- Adicet Bio, Inc. lease, cost for fiscal 2022 was $3.94M, a 8.31% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $854.00K 10-Q · filed 2026-08-05 | $1.68M derived: sum of 2 quarters · filed 2026-08-05 | $2.62M derived: sum of 3 quarters · filed 2026-08-05 | $3.46M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $823.00K 10-Q · filed 2026-05-13 | $1.77M derived: sum of 2 quarters · filed 2026-05-13 | $2.61M derived: sum of 3 quarters · filed 2026-05-13 | $3.63M derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | $946.00K derived: 10-K 12 month − 3 quarters · filed 2026-03-12 | $1.79M derived: sum of 2 quarters · filed 2026-03-12 | $2.80M derived: sum of 3 quarters · filed 2026-03-12 | $3.79M 10-K · filed 2026-03-12 |
| 2025-09-30 | $840.00K 10-Q · filed 2025-11-05 | $1.86M derived: sum of 2 quarters · filed 2025-11-05 | $2.85M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2025-06-30 | $1.02M 10-Q · filed 2025-08-07 | $2.01M derived: sum of 2 quarters · filed 2025-08-07 | ||
| 2025-03-31 | $990.00K 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $3.95M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $991.00K 10-Q · filed 2024-11-06 | $1.98M derived: sum of 2 quarters · filed 2024-11-06 | $988.78M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2024-06-30 | $984.00K 10-Q · filed 2024-08-13 | $987.79M derived: sum of 2 quarters · filed 2024-08-13 | ||
| 2024-03-31 | $986.81M 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $3.99M 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $1.01M 10-Q · filed 2023-11-08 | $1.97M derived: sum of 2 quarters · filed 2023-11-08 | $2.98M derived: sum of 3 quarters · filed 2023-11-08 | $5.94M derived: sum of 4 quarters · filed 2024-03-19 |
| 2023-06-30 | $959.00K 10-Q · filed 2023-08-09 | $1.97M derived: sum of 2 quarters · filed 2023-08-09 | $4.93M derived: sum of 3 quarters · filed 2024-03-19 | $4.90M derived: sum of 4 quarters · filed 2024-03-19 |
| 2023-03-31 | $1.01M 10-Q · filed 2023-05-09 | $3.97M derived: sum of 2 quarters · filed 2024-03-19 | $3.94M derived: sum of 3 quarters · filed 2024-03-19 | $3.96M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $2.93M derived: sum of 2 quarters · filed 2024-03-19 | $2.95M derived: sum of 3 quarters · filed 2024-03-19 | $3.94M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$10.00K derived: sum of 2 quarters · filed 2022-11-08 | $973.00K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $1.01M 10-Q · filed 2022-08-10 | ||
| 2022-03-31 | $983.00K 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $4.29M 10-K · filed 2023-03-15 | |||
| 2020-12-31 | $950.00K 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |